Literature DB >> 16977637

Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow.

Elena A Jones1, Anne English, Sally E Kinsey, Liz Straszynski, Paul Emery, Frederique Ponchel, Dennis McGonagle.   

Abstract

BACKGROUND: To study the biology of rare bone marrow (BM) multipotent mesenchymal stromal cells (MSCs), recognized protocols are needed. Colony-forming unit-fibroblast (CFU-F) assays have historically been used for the enumeration of MSCs. However, the need to isolate and further analyze MSCs requires new strategies based on cell surface markers. The purpose of this work was to verify the phenotype of BM MSCs in vivo and to develop flow cytometry-based methods for their evaluation.
METHODS: Pre-enrichment with D7-FIB-conjugated microbeads, cell sorting for CD45low D7-FIB+ LNGFR+ cells, and CFU-F assay were used to confirm the phenotype of BM MSCs in vivo. Further phenotypic characterization of MSCs was performed using three-color flow cytometry following pre-enrichment or by direct four-color flow cytometry. The sensitivity of direct flow cytometry/rare event analysis for the accurate enumeration of MSCs was validated using 85 samples from patients with neoplastic BM diseases.
RESULTS: In normal BM, a significant correlation was found between the frequencies of CFU-Fs and CD45low D7-FIB+ LNGFR+ cells (n = 19, R = 0.719, P = 0.001). Following cell sorting, 15% of these cells were clonogenic. The same cells were enriched using LNGFR-based positive selection, CD45/Glycophorin A-based depletion, or plastic adherence. CD45low D7-FIB+ LNGFR+ cells expressed classic makers of cultured MSCs CD73/SH3 and CD105/SH2 and markers of stromal reticular cells CD106/VCAM and alkaline phosphatase. Novel markers were identified including leukemia inhibitory factor receptor and gp130. CD45low D7-FIB+ LNGFR+ cells were increased fourfold in the floating fat fraction of normal BM aspirates. Their frequency was decreased in chronic lymphocytic leukemia (threefold, n = 13, P = 0.049) and chronic myelogenous leukemia (ninefold, n = 11, P = 0.001) compared with that in age-matched controls (n = 26 and n = 31, respectively).
CONCLUSIONS: This study demonstrates the usefulness of flow cytometry-based methods for the detection, enumeration and further phenotypic analysis of BM MSCs. These findings have broad applications for the future evaluation of BM MSCs in health and disease. Copyright 2006 International Society for Analytical Cytology.

Entities:  

Mesh:

Year:  2006        PMID: 16977637     DOI: 10.1002/cyto.b.20118

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  42 in total

1.  Long-term engraftment of multipotent mesenchymal stromal cells that differentiate to form myogenic cells in dogs with Duchenne muscular dystrophy.

Authors:  Yuko Nitahara-Kasahara; Hiromi Hayashita-Kinoh; Sachiko Ohshima-Hosoyama; Hironori Okada; Michiko Wada-Maeda; Akinori Nakamura; Takashi Okada; Shin'ichi Takeda
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

2.  Mesenchymal Stem or Stromal Cells: Toward a Better Understanding of Their Biology?

Authors:  Ulrich Lindner; Jan Kramer; Jürgen Rohwedel; Peter Schlenke
Journal:  Transfus Med Hemother       Date:  2010-03-15       Impact factor: 3.747

3.  Mesenchymal stem cells improve healing of the cornea after alkali injury.

Authors:  Diamantis Almaliotis; Georgios Koliakos; Eleni Papakonstantinou; Anastasia Komnenou; Angelos Thomas; Spiros Petrakis; Ilias Nakos; Eleni Gounari; Vasileios Karampatakis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-23       Impact factor: 3.117

Review 4.  Reamer-irrigator-aspirator indications and clinical results: a systematic review.

Authors:  George Cox; Elena Jones; Dennis McGonagle; Peter V Giannoudis
Journal:  Int Orthop       Date:  2011-01-18       Impact factor: 3.075

5.  CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties.

Authors:  Selim Kuçi; Zyrafete Kuçi; Hermann Kreyenberg; Erika Deak; Kathrin Pütsch; Sabine Huenecke; Chandrasekhar Amara; Stefanie Koller; Eva Rettinger; Manuel Grez; Ulrike Koehl; Hatixhe Latifi-Pupovci; Reinhard Henschler; Torsten Tonn; Dorothee von Laer; Thomas Klingebiel; Peter Bader
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

Review 6.  CD271 as a marker to identify mesenchymal stem cells from diverse sources before culture.

Authors:  María Álvarez-Viejo; Yolanda Menéndez-Menéndez; Jesús Otero-Hernández
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

7.  Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic leukemia.

Authors:  Jessie-F Fecteau; Davorka Messmer; Suping Zhang; Bing Cui; Liguang Chen; Thomas J Kipps
Journal:  Blood       Date:  2012-12-18       Impact factor: 22.113

8.  The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice.

Authors:  Ryang Hwa Lee; Min Jeong Seo; Andrey A Pulin; Carl A Gregory; Joni Ylostalo; Darwin J Prockop
Journal:  Blood       Date:  2008-09-25       Impact factor: 22.113

9.  Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID-repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages.

Authors:  Alexandra Briquet; Sophie Dubois; Sandrine Bekaert; Marie Dolhet; Yves Beguin; André Gothot
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

10.  Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells.

Authors:  M Hirotsu; T Setoguchi; Y Matsunoshita; H Sasaki; H Nagao; H Gao; K Sugimura; S Komiya
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.